2017 American Transplant Congress Archives - Page 2 of 181

D-Dimer Level, in Association with Humoral Responses, Negatively Correlates with Survival of Porcine Islet Grafts in Nonhuman Primates with Immunosuppression.

H. Kang,¹ H. Lee,¹ E. Park,¹ J. Kim,² B. Min,² C.-G. Park.²
Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID).

S. Anand,^1,3 D. Miller,¹ G. Chipman,² D. Morris,^1,3 T. Srinivas.¹
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.

S. Stead,¹ S. Kireta,² S. McInnes,³ P. Rose,¹ S. Jesudason,^1,2 S. Grey,⁴ D. Rojas-Canales,² R. Carroll,^1,2 N. Voelcker,⁴ P. Coates.^1,2
De Novo DSA Positivity Is Associated with a Higher Rate of Post-Transplant Bacterial and Viral Infections.

A. Brooks,¹ L. Rebellato,² K. Briley,² P. Bolin,² S. Kendrick,³ A. Maldonado,⁴ C. Haisch,² M. Everly.¹
De Novo DSA with T Cell Mediated Rejection (TCMR) Leads to Early Allograft Scarring and Dysfunction.

A. Cherukuri, A. Sharma, M. Mangiola, P. Sood, P. Randhawa, A. Zeevi, R. Mehta, S. Hariharan.
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.

J. Lee,¹ K. Huh,¹ J. Ha,² C.-K. Oh,³ M. Ju,⁴ C.-D. Kim,⁵ H. Cho,⁶ C. Jung,⁷ B. Lim,⁸ Y. Kim.¹
De Novo Malignancy Occurrence After Kidney Transplantation in HLA-Sensitized Patients Treated with B-Cell Targeting Therapy.

L. Couzi,^1,2,3 P. Davis,¹ J. Visentin,^1,2,3 B. Taton,¹ G. Guidicelli,¹ H. Kaminski,^1,2,3 P. Merville,^1,2,3 T. Bachelet.⁴
De Novo, Non-Donor Specific HLA Antibodies Are Associated with Inferior Allograft Outcomes After Kidney and Simultaneous Kidney-Pancreas Transplantation.

S. Hassan,¹ G. Lucisano,¹ E. Santos,² D. McKeown,³ D. Goodall,¹ A. Gueret-Wardle,¹ A. McLean,¹ P. Brooks,² M. Willicombe,¹ D. Taube.¹
Death After Kidney Transplantation: Assessment of Pre- and Peri-Transplant Risk Factors and of Time-Varying Risk Factors from the Post-Transplant Course.

I. Scheffner,¹ T. Abeling,¹ A. Karch,¹ M. Mengel,² V. Broeker,³ A. Koch,¹ H. Haller,¹ A. Schwarz,¹ W. Gwinner.¹
Deceased Donor-Initiated Non-Simultaneous Extended Altruistic Donor Chains Through the Military Share Program.

M. Rees,^1,2 O. Ekwenna,¹ E. Elster,³ A. Patel,³ D. Murtagh, Jr,¹ A. Roth,⁴ K. Krawiec,⁵ J. Arrington,⁶ I. Ashlagi,⁴ J. Hawksworth.³
Deceased Donors with a History of IV Drug Use and Donor Derived Hepatitis C Virus.

D. Kaul,¹ M. Clark,² M. Michaels,¹ S. Tlusty,² C. Wolfe.¹
Decellularized Rat Liver Scaffolds Support Survival and Metabolic Function of Multilineage Allogenic Cells.

W. Hassanein, A. Werdesheim, A. Cimeno, B. Buckingham, A. Khalifeh, M. Uluer, J. Harrison, D. Parsell, C. Drachenberg, R. Barth, J. LaMattina.
Deciphering the Mechanism of Remote Ischemic Preconditioning and Its Potential Benefits in Ischemia/Reperfusion Injury by Metabolomics.

S. Cho, S.-I. Min, S.-Y. Kim, M.-J. Cho, W. Cho, S. Ahn, S.-K. Min, J. Ha.
Decision Tree Analysis of Renal Transplantation Recipients Outcomes: A Single Center Data Mining in the Big Data Era.

J. Zhou,¹ Y. Shen,² R. Wang,¹ H. Huang,¹ J. Wu,¹ J. Chen.¹
Defining a BKV Cutt-Off and Profile for Early Detection of BKV Associated Nephropathy.

C. Nihei,¹ F. Agena,¹ F. Paula,¹ D. David,¹ M. Fink,³ L. Pierrotti,² E. David-Neto.¹
Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction.

N. Lange,^1,2 D. Salerno,¹ C. Sammons.²
Delayed Graft Function and Long-Term Graft Survival in DBD and DCD Kidney Recipients.

A. Massie, D. Segev.
Delayed Graft Function[mdash]Less Ominous for ARF or DCD Recipients?

M. Barrett, A. Smith, K. Woodside, R. Sung.
Delayed Renal Implantation Improves Survival Following Simultaneous Liver-Kidney Transplantation in High Acuity Recipients.

K. Lunsford,¹ V. Agopian,² A. Saharia,¹ J. Balough,¹ C. Mobley,¹ S. Gordon-Boroughs,¹ H. Gritsch,² H. Podder,¹ R. Knight,¹ G. Danovitch,² X. Li,¹ A. Gaber,¹ R. Busuttil,² R. Ghobrial.¹
Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Non-Human Primates: The Immunomodulatory Effect of Donor Bone Marrow Transplantation Does Not Prevent the Development of Chronic Rejection in the Absence of Durable Mixed Chimerism.

Z. Ng, A. Lellouch, A.-R. Gama, I. Schol, I. Rosales, R. Colvin, L. Geoghegan, J. Kurtz, C. Cetrulo.
Deleting LAG-3 Accelerates Cardiac Allograft Rejection and Augments T Cell Memory in Mice.

J. Erfe,^1,2 C. Yang,¹ D. Ndishabandi,¹ I. Rosales,¹ R. White,¹ P. Russell,¹ R. Colvin,¹ J. Madsen,¹ A. Alessandrini.¹
Dementia and Alzheimer's Disease Among Older Kidney Transplant Recipients.

M. McAdams DeMarco, S. Bae, N. Chu, A. Gross, C. Brown IV, E. Oh, P. Rosenberg, K. Neufeld, R. Varadhan, M. Albert, J. Walston, D. Segev.
Dendritic Cell Expression of Rictor (mTORC2), but Not Raptor (mTORC1), Protects Against Renal Ischemia-Reperfusion Injury.

H. Dai,^1,3 N. Rogers,^1,2 A. Watson,¹ D. Fantus,¹ A. Thomson.¹
Dendritic Cells That Highly Express SOCS1 Induce T-Cell Hypo-Responsiveness and Prolong Islet Allograft Survival.

R. Deng, X. Lu, M. Chen, Z. Xue, X. Zhang, J. Xu, L. Wu, Y. Ma.
Depletion of T-Cells from G-CSF Mobilized Human PBMC Prevents Acute GVHD in NSG Mice.

Y. Huang, H. Xu, A. Merchak, A. Chhabra, Y. Wen, L. Kahn, S. Ildstad.
Depressive Symptoms, Physical Frailty, and Kidney Transplant Adverse Outcomes.

J. Konel, F. Warsame, H. Ying, C. Haugen, M. McAdams DeMarco, D. Segev.
Describing the Effects of the Antibiotic Regimen Immediate Post Multi-Visceral Transplant in the Pediatric Population on the Time to First Serious Bacterial Infection.

B. Chatani,¹ J. Garcia,² C. Biaggi,² T. Beduschi,³ A. Tekin,³ R. Vianna,⁴ I. Gonzalez.⁵
Desensitization Regimen for the Patients with High Isoagglutinin Titers to Undergo Adult ABO-Incompatible Living Donor Liver Transplantation.

W.-C. Lee, C.-F. Lee, T.-H. Wu, Y.-C. Wang, C.-H. Cheng, T.-J. Wu, H.-S. Chou, K.-M. Chan.
Desensitization versus Deceased Donor Kidney Transplantation: What to Choose When Both Become Available?

B. Orandi,¹ X. Luo,² J. Garonzik-Wang,² R. Montgomery,³ D. Segev.²
Designing a Novel Selective Immunoproteasome Inhibitor Reveals a Critical Role of the IP and STAT5 Pathway in Regulating T Cell Exhaustion and Promoting Long Term Heart Allograft Acceptance.

S. Routray, E. Karreci, M. Uehara, J. Assaker, A. Mihali, S. Eskandari, L. Riella, R. Abdi, Y. Kawano, C. Nathan, G. Lin, J. Azzi.
Detection of Right Ventricular Dilation and Dysfunction by Transthoracic Echocardiography Predicts Renal Transplant Outcomes.

F. Tinney Jr,¹ S. Lazar,² A. Naik,² M. Samaniego-Picota,² N. Bhave.²
Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts.

K. Keslar,¹ A. Zmijewska,² J. Chen,² K. Newell,³ P. Heeger,⁴ R. Mannon,² R. Fairchild.¹
Detection of Specific B Cell Memory to the Perlecan LG3 Antigen in the Normal Immune Repertoire.

L. Padet,^1,2,3 M. Dieude,^1,2 B. Yang,^1,2,3 J. Turgeon,^1,2 H. Cardinal,^1,2 M.-J. Hebert.^1,2,3
Determinants of Severe Interstitial Fibrosis in Kidney Allografts: Major Impact of Circulating Donor-Specific Anti-HLA Antibodies.

C. Gosset, D. Viglietti, M. Rabant, E. Pillebout, J. Taupin, D. Glotz, C. Legendre, J. Duong Van-Huyen, A. Loupy, C. Lefaucheur.
Determinants of Successful Use of Sirolimus in Renal Transplantation.

M. Naik,¹ W. Gwinner,² W. Arns,³ E. Basic,¹⁰ K. Budde,¹ F. Diekmann,⁴ M. Fischereder,⁵ J. Goßmann,⁶ K. Heller,⁷ N. Heyne,⁸ J.-S. Jürgensen,¹ C. Morath,⁹ U. Riester.¹⁰
Development and Validation of an FLF-Transplant Score to Predict Mortality of Patients with Fulminant Liver Failure.

Z. Guo, B. Chen, X. He, G. Chen.
Development and Validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) Criteria to Assess Drug Related Problems in Outpatient Renal Transplant Population.

L. El Raichani,¹ Q. Du,¹ A. Mathieu,¹ S. Almassy,¹ L. Lalonde,¹ N. Boudreau,¹ E. Gélinas-Lemay,¹ D. Berbiche,³ H. Cardinal.²
Development of an Anti-HLA Antibody-Producing Humanized Mouse Model.

S. Yanagawa, H. Tahara, H. Ohdan.
Development of an Automatic Regulated Normothermic Kidney Preservation Device for Long-Term Organ Perfusion.

A. Weissenbacher,¹ O. Boubriak,² L. Lo Faro,¹ R. Ploeg,¹ J. Hunter,¹ D. Voyce,³ N. Mikov,³ A. Cook,³ C. Coussios,² P. Friend.¹
Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients.

H. Khamash, L. Archambault, M. Buras, H. Kosiorek, M. Pando, K. Reddy, B. Kaplan, R. Heilman.
Development of Transplant Glomerulopathy in Recipients with Antibody Mediated Rejection: Activation of Inflammatory Pathway Through Renal Poly (ADP-Ribose) Polymerase (PARP).

B. Ozdemir,¹ F. Ozdemir,² E. Baskin,² M. Haberal.³
Dexamethasone Prolongs Cardiac Allograft Survival in a Murine Model Through Myeloid-Derived Suppressor Cells.

T. Nakao,¹ T. Nakamura,¹ K. Masuda,¹ T. Matsuyama,¹ H. Ushigome,¹ E. Ashihara,² N. Yoshimura.¹
Diabetes in Liver Transplantation: Evaluation of Management and Associated Clinical Outcomes.

A. Rogers,² N. Patel,² H. Meadows,² A. Mardis,² J. Fleming,² C. Perez,² I. Lee,² M. Sell,² B. O'Brien,² D. Taber,¹ K. Chavin,¹ D. Dubay,¹ C. Mardis,² N. Pilch.¹
Diagnostic Bronchoscopy in Kidney Transplant Recipients with Acute Respiratory Failure: Risk or Value?

D. Khadzhynov, J. Deissler, F. Halleck, L. Lehner, K. Budde, O. Staeck.
Dialysis Facility Providers' Awareness of Racial Disparities in Kidney Transplantation.

J. Kim, M. Basu, L. Plantinga, C. Escoffery, S. Pastan, R. Patzer.
Differences in Kinetics of IFN-y Production Between Endogenous and Allotransplant-Induced Memory T Cells.

B. Gonzalez-Nolasco, J. Marino, W. Orent, G. Benichou.
Differences in Racial and Sex Disparities in Liver Transplantation Outcomes Between Older and Younger Adult Recipients.

Q. Huang, C. Haugen, X. Luo, A. Massie, M. McAdams-DeMarco, D. Segev.
Different Prognostic Factors for Early and Late Recurrence After Adult Living Donor Liver Transplantation for Hepatocellular Carcinoma.

S. Hong, K.-W. Lee, H.-S. Kim, S.-W. Ahn, K. Yoon, H. Kim, N.-J. Yi, K.-S. Suh.
Differential Effect of Antibody Removal on ABO Blood Group Type Chain Specific Antibodies Over Time.

A. Bentall,¹ M. Jeyakanthan,² J. Pearcey,² B. Motyka,² C. Cairo,³ T. Lowary,³ J. Buriak,⁴ L. West,² S. Ball.¹
Differential Effects of Immunosuppressive Drugs on DNA Methylation in T Cells.

F. Peters,¹ A. Peeters,¹ L. Hofland,² M. Betjes,¹ K. Boer,¹ C. Baan.¹
Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.

D. Fantus, Y. Ono, H. Dai, S. Yokota, O. Yoshida, A. Thomson.
Differential Expression of Long Noncoding RNAs During Cardiac Allograft Rejection.

G. Gu, H. Hang, T. Lu, Q. Xia.
Differential Suppressive Effects of Costimulatory Blockade (CD28/B7), Anti-IL6R, Bruton's Tyrosine Kinase and Janus Kinase Inhibition on De Novo vs. Recall Alloantibody Responses: Are Combined Drug Therapy Approaches Desirable?

I. Kim, G. Wu, N.-N. Chai, A. Klein, S. Jordan.
Digital Image Analysis of Pediatric Liver Allograft Biopsies Correlates with METAVIR Fibrosis Score.

R. Fischer,¹ S. Foster,² J. Daniel,¹ R. Hendrickson,¹ W. Andrews,¹ A. Kats.¹
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).

J. Korula, T. Shah, E. Ranger, E. Barba, D. Vu, R. Naraghi.
Direct Comparison of Hypothermic and Normothermic Organ Preservation in a Porcine Ex-Vivo Kidney Model.

N. Vallant,^1,2 B. Sandhu,¹ N. Wolfhagen,¹ C. Pusey,¹ V. Papalois.¹
Direct Intrahepatic Delivery of Pegylated-Catalase Is Protective in a Rat Ischemia-Reperfusion Injury Model.

E. Beal,¹ S. Black,¹ J. Kim,¹ V. Velazquez,² K. Washburn,¹ D. Hayes Jr.,³ B. Whitson.¹
Discrepancies in Perceived and Measured Cognitive Abilities in Transplant Recipients.

A. Gupta,¹ J. Mahanken,² J. Klein,¹ D. Johnson,³ J. Burns.⁴
Disease Progression on Neoadjuvant Chemotherapy Is a Strong Predictor of Recurrence for Pediatric Hepatoblastoma.

M. Kueht,¹ S. Commander,¹ T.-A. Ha,¹ A. Rana,^1,2 Y. Shi,¹ S. Vasudevan,^1,2 J. Goss.^1,2
Disparities in Access to the Liver Transplant Wait List: A Statewide Analysis.

Y. Bababekov, D. Chang, Y.-C. Hung, J. Adler, S. Stapleton, J. Markmann, H. Yeh.
Disparity in Transplant Referral Patterns Based on Physician Dependent Variables.

V. Loy, A. Rzepczynski, S. Bello, C. Blackburn, A. Lu.
Distinctive Molecular Features of Antibody-Mediated versus T-Cell Mediated Rejection in Facial Transplantation.

R. Lopdrup, T. Win, N. Murakami, J. Teague, A. Chandraker, G. Murphy, C. Lian, E. Bueno, B. Pomahac, R. Clark, L. Riella.
DNA Hypermethylation Caused by Ischemia in Kidney Transplants Predicts Future Chronic Injury to the Allograft.

L. Heylen,^1,2,3,4 B. Thienpont,^3,4 M. Naesens,^1,2 J. Depreeuw,^3,4 P. Busschaert,^3,4 D. Kuypers,^1,2 I. Jochmans,^2,5 D. Monbaliu,^2,5 J. Pirenne,^2,5 D. Lambrechts,^3,4 B. Sprangers.^1,2
DNA Methylation Dynamics from Ischemia/Reperfusion Injury to Long-Term Allograft Function.

V. Bontha,¹ D. Maluf,¹ M. Dozmorov,² D. Bagchi,¹ K. Archer,³ V. Mas.¹
Do Perioperative Blood Transfusions Influence Kidney Transplant Outcomes in the Modern Era?

J. Lineen, J. Trac, Y. Li, O. Famure, J. Kim.
Does an Indeterminate Result on Pre-Transplantation Tuberculosis Interferon Gamma Release Assay Predict Risk for Post-Transplantation Infection or Rejection?

A. Zimmer,¹ R. Razonable.²
Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?

N. O'Neill, T. Zhang, X. Cheng, W. Sun, G. Braileanu, I. Tatarov, W. Hassanein, A. Azimzadeh, R. Pierson.
Does Choice of Induction Agent Affect Outcomes in Kidney Transplants from Deceased Donors with Acute Kidney Injury and Prolonged Cold Ischemia Time?

G. Dube, S. Mohan, M. Chiles.
Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents?

J. Putra,¹ T. Schiano,² M. Fiel.¹
Does EBV Viremia at Time of Transplant Have a Negative Impact on Transplant Outcomes?

P. Verghese, H. Balfour, D. Schmeling, J. Grimm, S. Chinnakotla, A. Matas.
Does Gender Affect Renal Transplant Outcomes?

A. Patel, R. Prashar.
Does Histologic Grade in BK Polyoma Nephropathy Associate with Viral Load, Allograft Dysfunction or Allograft Loss? A Single Center Experience.

M. Swee,¹ S. Kuppachi,¹ M. Fraer,¹ P. Rastogi,² P. Ten Eyck,¹ M. Sanders.¹
Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.

A. Babu,^1,2,3 D. Briggs,³ D. Mitchell,¹ N. Krishnan,² R. Higgins,¹ S. Daga.^1,2,4
Does Pancreas Transplantation for the Patients with Diabetes Showed Significant Survival Benefit?

J. Choi, J. Jung, S. Chun, S. Shin, Y. Kim, D. Han.
Does Simultaneous Liver Kidney Transplant in Patients with MELD ≥35 on Renal Replacement Therapy at the Time of Transplant Improve Outcome?

B. Ali, C. Gadiparthi, G. Cholankeril, S. Satapathy, J. Eason, S. Nair.
Does the Model for End Stage Liver Disease (MELD) Score Predict Outcome in Total Artificial Heart Patients?

M. Rafiei, J. Moriguchi, M. Kittleson, J. Patel, T. Aintablian, E. Passano, R. Sharoff, J. Kwan, E. Kransdorf, D. Chang, L. Czer, J. Kobashigawa, F. Arabia.
Dominant Role of Clonal Deletion in Achieving Immune Tolerance After Unrelated Cord Blood Transplantation.

P. Szabolcs,^1,2 X. Chen,¹ M. Hill.¹
Donation After Cardiac Death (DCD) Liver Transplantation (LT) Is Not Associated with Post-LT Renal Dysfunction.

H. Wadei, M. Mai, D. Lee, K. Croome, B. Rosser, A. Keaveny, B. Taner.
Donation After Circulatory Death (DCD) Kidneys Are More Likely to Be Discarded than Kidneys from Neurologically Brain Dead Donors (NBD).

J. Gill,¹ C. Rose,¹ J. Lesage,¹ Y. Joffres,¹ J. Gill,¹ K. O'Connor.²
Donor Batf3-Dependent Dendritic Cells Initiate Acute Rejection in a Skin Transplantation Model.

T. Borges, N. Murakami, L. Riella.
Donor Age > 50 Years and CIT Longer Than 18 Hour Are Independent Risk Factors for One Year Graft Survival in Renal Transplant Form Uncontrolled Donors After Circulatory Death (uDCD).

M. Molina, E. Gutierrez, E. Gonzalez, E. Morales, J. Cabrera, A. Andres.
Donor Age Is the Most Important Predictor of Longterm Graft Function in Simultaneous Pancreas-Kidney Transplantation from Donors After Cardiac Death.

J. Chen,¹ D. Mikhail,^1,2 H. Sharma,³ A. Hijazi,¹ D. Nap,¹ L. Stitt,⁴ J. Jevnikar,⁵ M. Cooper,⁶ P. Luke,^1,2 A. Sener.^1,2
Donor and Recipient Factors Important in Determining the Estimated GFR Difference Between Living Donor and Recipient Pairs Six Months After Transplant.

D. Keith.
Donor and Recipient Outcomes with Trans-Umbilical Laparoendoscopic Single-Site Donor Nephrectomy.

H. El Hennawy, A. Fahmy.
Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies.

A. Ralph,^1,2 P. Butow,¹ C. Hanson,^1,2 S. Chadban,^1,3 J. Chapman,¹ J. Craig,^1,2 J. Kanellis,⁴ G. Luxton,⁵ A. Tong.^1,2
Donor Body Mass Index and Utilization of Liver Biopsy: An Evaluation of National Practices and Organ Utilization.

J. Steggerda,¹ D. Marguiles,¹ D. Malinoski,² M. Bloom.¹
Donor Creatinine and Graft Outcomes in Pediatric Kidney Transplant Recipients.

N. Hayde, M. Del Rio.
Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation.

V. Hellström,¹ G. Tufveson,¹ A. Wallgren,² A. Loskog,² E. Larsson,² T. Töttermann,² M. Bengtsson,² A. Laurell,² C. Lundberg,¹ B. Holmström,¹ G. Enblad,² T. Lorant.¹
Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).

C. Wolfe,¹ M. Clark,² S. Tlusty,² D. Kaul,¹ M. Michaels.¹
Donor Factors Show Low Impact on Patient and Kidney Allograft Outcomes: A Paired Analysis of Left/Right Deceased Donor Kidney Pairs.

T. Schachtner,^1,2,3 M. Stein,² P. Reinke.^1,2
Donor Families' Perspectives of the Harms of Failed Donation After Circulatory Death: A Qualitative Analysis.

L. Taylor,¹ A. Buffington,¹ S. Joseph,³ N. Fost,² M. Schwarze.¹
Donor Genetic Background Determines the Severity of Delayed Graft Function Following Kidney Transplantation in Mice.

L. Qiu, J.-J. Wang, X. Yeap, Z. Zheng, M. He, M. Abecassis, Z. Zhang.
Donor Kidney Volume Predicts One and Three Month eGFR in Live Donor Kidney Transplant Recipients.

D. Al-Adra,¹ M. Lambadaris,² A. Barbas,¹ Y. Li,² N. Goldaracena,¹ O. Famure,² S. Kim,² A. Ghanekar.¹
Donor Leukocytes Are Eliminated by the Host's Immune System Shortly After Skin Transplantation in Mice.

J. Marino, B. Gonzalez-Nolasco, G. Benichou.
Donor Lymphoid Chimerism in Early Recognition and Prediction of Clinical Outcome Caused by Acute Graft versus Host Disease After Solid Organ Transplant.

A. Zhang,¹ Y. Sun,² K. Hashimoto,⁴ M. Fujiki,⁴ M. Askar,³ J. Fung,⁵ C. Miller,⁴ K. Abu-Elmagd,⁴ B. Eghtesad.⁴
Donor Macrophage Depletion from CMV-Latently Infected Hearts Abrogates CMV-Accelerated Chronic Rejection.

J. Burg,¹ T. Andoh,² N. Haese,² I. Jones,² S. Orloff,¹ D. Streblow.²
Donor Recipient Matching Based on HLA Epitopes Improves Outcome in Kidney Transplant Recipients.

O. Staeck,¹ M. Niemann,³ F. Halleck,¹ D. Khadzhynov,¹ C. Schönemann,² P. Reinke,¹ E. Spierings,⁴ K. Budde,¹ N. Lachmann.²
Donor SIRPa Polymorphism Modulates the Innate Immune Response to Allogeneic Grafts.

H. Dai,¹ A. Friday,¹ K. Abou-Daya,¹ A. Williams,¹ M. Oberbarnscheidt,¹ J. Danska,² F. Lakkis.¹
Donor Smoking History Associated with Increased Risk of Death Following Lung Transplantation, but Lower Risk of Bronchiolitis Obliterans Syndrome.

S. Burger, M. Eberlein, J. Keech, E. Arshava, T. Pena, S. Larson, J. Klesney-Tait, K. Parekh.
Donor Warm Ischemic Time >80min Is an Important Predictor of Kidney Graft Survival from Donors After Cardiac Death.

J. Chen,¹ D. Mikhail,² H. Sharma,³ A. Hijazi,¹ D. Nap,¹ L. Stitt,⁴ J. Jevnikar,⁵ M. Cooper,⁶ P. Luke,² A. Sener.²
Donor-Derived Cell-Free DNA Correlates with Antibody-Mediated Rejection in Kidney Allografts.

R. Bloom,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Sninsky,⁴ J. Yee,⁴ D. Brennan.⁵
Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.

D. Brennan,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ J. Sninsky,⁴ R. Woodward,⁴ J. Yee,⁴ R. Bloom.⁵
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.

J. Bromberg,¹ D. Brennan,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Yee,⁴ J. Sninsky,⁴ R. Bloom.⁵
Donor-Derived Cell-Free DNA Parallels Increases in Donor Specific Antibodies in Pediatric Kidney Transplant Recipients.

D. Stoltz,¹ A. Brubaker,¹ M. Grskovic,² R. Woodward,² A. Gallo.¹
Donor-Derived Cell-Free DNA Predicts Biopsy-Proven Acute Cellular Rejection in Pediatric Kidney Transplant Recipients.

D. Stoltz,¹ A. Brubaker,¹ M. Grskovic,² R. Woodward,² A. Gallo.¹
Donor-Derived Nonclassical Monocytes Produce MIP-2 to Recruit Recipient Neutrophils and Cause Ischemia Reperfusion Injury After Lung Transplant.

S. Chiu,¹ Z. Zheng,¹ M. Akbarpour,¹ R. Fernandez,¹ A. McQuattie-Pimentel,¹ P. Reyfman,¹ K. Anekalla,¹ D. Kreisel,² H. Perlman,¹ G. Budinger,¹ A. Misharin,¹ A. Bharat.¹
Donor-Specific B Cell Responses: Predicting the Future of Kidney Transplants.

M. Cascalho,¹ E. Farkash,² L. Adam,¹ M. Samaniego,³ J. Platt.
Donor/Recipient Matching Using the Creatinine Clearance Match Ratio (CCMR) Is Superior to the Kidney Donor Profile Index (KDPI) Predicting Early but Not Late Outcomes for Deceased Donor Kidney Transplantation.

J. Halldorson, N. Karimi.
Down but Not Out: Leucopenia Can Be Safely Treated with Reduction in Immunosuppression without Increasing Risk to the Kidney Allograft.

A. Gilbert,¹ A. Vergottini,¹ A. Karabala,¹ M. Grafals,¹ B. Javaid,¹ J. Moore,¹ J. Verbesey,² P. Abrams,² S. Ghasemian,² M. Cooper.²
Down-Regulation of Nuclear HMGB1 by Small Interfering RNA Protects Against Liver Ischemia-Reperfusion Injury.

G. Zhao, C. Fu, L. Wang, L. Zhu, S. Chen, G. Chen.
Dramatic Shifts in Prognosis, Outcomes and Baseline Risk Among Wait Listed Kidney Transplant Candidates in the United States.

J. Schold, E. Poggio, L. Buccini, S. Flechner, J. Augustine, D. Goldfarb.
DSA Presence Does Not Affect Renal Histology and Clinical Outcome in Chronic Active Antibody Mediated Rejection.

K. Sablik,¹ M. Clahsen–van Groningen,¹ C. Looman,¹ J. Damman,¹ D. Roelen,² M. van Agteren,¹ M. Betjes.¹
Dual Costimulatory Blockades Failed to Achieve Transplant Tolerance Despite Induction of Mixed Chimerism in NHPs.

T. Oura,¹ K. Hotta,¹ I. Rosales,² A. Dehnadi,¹ J. Lei,¹ J. James Markmann,¹ M. Matsunami,¹ J. Paster,¹ I. Hanekamp,¹ K. Pruner,¹ K. Kawai,¹ D. Ndishabandi,² R.-N. Smith,² B. Cosimi,¹ T. Kawai.¹
Dual Role for Caspase-3 in the Regulation of Tubular and Microvascular Damage Post-Renal Ischemia-Reperfusion Injury.

B. Yang,^1,2,3 S. Lan,^1,2,3 N. Patey,^1,3,4 J. Turgeon,^1,3 M. Dieudé,^1,3 M.-J. Hébert.^1,2,3
Dual Targeting of Costimulation and Proteasome to Desensitize and Prolong Graft Survival of Sensitized Nonhuman Primates.

J. Kwun,¹ C. Burghuber,¹ M. Manook,¹ B. Ezekian,¹ J. Park,^1,2 K. Freishlag,¹ J. Yoon,¹ N. Iwakoshi,³ A. Farris,⁴ S. Knechtle.¹
Dual Targeting with Carfilzomib and Tocilizumab Abrogates Antibody-Mediated Rejection and Prolongs Survival in a Highly Sensitized Rhesus Model of Kidney Transplantation.

B. Ezekian, J. Kwun, M. Manook, K. Freischlag, V. Curfman, E. Branum, J. Park, J. Yi, S. Jordan, S. Knechtle.
Dual Treatment of Suboptimal Doses of CsA and MSC Infusion Fully Prevents Acute Rejection in an Allogenic Model of Renal Transplantation.

L. de Ramon,¹ A. Merino,¹ E. Ripoll,¹ N. Bolaños,¹ M. Gomà,³ J. Cruzado,^1,2 J. Grinyó,^1,2 J. Torras.^1,2
Dysregulated Innate Immune Response Is a Robust Predictor of Allograft Injury and Survival Across All Transplanted Organs.

T. Azad,¹ M. Donato,¹ L. Heylen,² S. Shen-Orr,³ T. Sweeney,¹ M. Naesens,² P. Khatri.¹